- Home
- EVER vs JANX Comparison
EVER vs JANX Comparison
Compare EVER & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVER | JANX |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.5M | 790.3M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EVER | JANX |
|---|---|---|
| Price | $16.49 | $13.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $27.00 | ★ $53.60 |
| AVG Volume (30 Days) | ★ 1.1M | 784.8K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 198.86 | N/A |
| EPS | ★ 2.63 | N/A |
| Revenue | ★ $163,349,000.00 | $10,000,000.00 |
| Revenue This Year | $14.68 | N/A |
| Revenue Next Year | $11.86 | $209.90 |
| P/E Ratio | $6.17 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.93 | $12.12 |
| 52 Week High | $30.03 | $35.34 |
Technical Indicators
Market Signals| Indicator | EVER | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 46.12 |
| Support Level | $13.93 | $13.01 |
| Resistance Level | $17.59 | $13.79 |
| Average True Range (ATR) | 0.83 | 0.55 |
| MACD | 0.35 | 0.07 |
| Stochastic Oscillator | 64.55 | 37.58 |
Price Performance
Historical ComparisonAbout EVER EverQuote Inc.
EverQuote Inc is engaged in the business activity of offering an online marketplace for insurance shopping, connecting consumers with insurance provider customers, which includes both carriers and agents. The online marketplace offers consumers to find relevant insurance quotes based on car insurance, home insurance, and life insurance. The platform of the company is driven by data science. The firm's data and technology platform match and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. It derives a majority of revenue from Direct channels.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.